60 yo w/ MSS T3N0 tumor: Would you offer Oncotype DX® assay? If not, what Tx recommend?
Would you offer an Oncotype DX® assay for an otherwise healthy 60-year-old patient with a Grade II, microsatellite stable (MSS) T3N0 (0 out of 20 nodes positive) tumor?
If not, what adjuvant systemic therapy would you likely recommend for this patient?
De Gramont A et al. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. Clin Colorectal Cancer 2011;10(4):218-26. Abstract
Gray RG et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011;29:4611-9. Abstract
Kelley RK, Venook AP. Prognostic and predictive markers in stage II colon cancer: Is there a role for gene expression profiling? Clin Colorectal Cancer 2011;10(2):73-80. Abstract
Love N et al. Is adjuvant oxaliplatin (Ox) overutilized in colon cancer (CC)? 408 cases from the practices of 102 oncologists. Gastrointestinal Cancers Symposium 2013;Abstract 479.
O’Connell MJ et al. Validation of the 12-gene colon cancer Recurrence Score result in NSABP C-07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (5FU) and 5FU/LV + oxaliplatin (5FU+Ox). Proc ASCO 2012;Abstract 3512.
Tournigand C et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30(27):3353-60. Abstract
Wolmark N. Prediction of risk recurrence with the Oncotype DX Colon Cancer assay and its application in treatment decision-making for patients with early colon cancer. Gastrointestinal Cancer Update, Issue 2, 2013. Available at: http://www.researchtopractice.com/GICU213/norman-wolmark-md/prediction-risk-recurrence-oncotype-dx-colon-cancer-assay-and-its-applicat.